GlobeNewswire: PDS Biotechnology Corporation Contains the last 10 of 286 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:05:02ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853060/0/en/PDS-Biotech-Announces-Clinical-Strategy-Update-and-Reports-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=53828PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results2024-03-27T11:30:00Z<![CDATA[Unique mechanism of action of the combination of PDS01ADC and Versamune® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial]]>https://www.globenewswire.com/news-release/2024/03/20/2849304/0/en/PDS-Biotechnology-Announces-Conference-Call-and-Webcast-for-Business-Update-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=53828PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results2024-03-20T12:00:00Z<![CDATA[PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell-activating platforms, today announced that the Company will provide a business update and release financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Following the release, management will host a conference call to review the financial results and provide a business update.]]>https://www.globenewswire.com/news-release/2024/03/13/2845346/0/en/PDS-Biotech-Announces-Publication-of-Preclinical-Research-and-Grant-of-U-S-Composition-of-Matter-Patent-for-Infectimune.html?f=22&fvtc=4&fvtv=53828PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®2024-03-13T12:00:00Z<![CDATA[Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants]]>https://www.globenewswire.com/news-release/2024/01/22/2813504/0/en/PDS-Biotech-Announces-Retirement-of-Lauren-V-Wood-M-D-and-Appointment-of-Kirk-V-Shepard-M-D-as-Chief-Medical-Officer.html?f=22&fvtc=4&fvtv=53828PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer2024-01-22T21:45:19Z<![CDATA[Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the Company Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the Company]]>https://www.globenewswire.com/news-release/2024/01/16/2809798/0/en/PDS-Biotech-to-Participate-at-B-Riley-Securities-4th-Annual-Oncology-Conference.html?f=22&fvtc=4&fvtv=53828PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference2024-01-16T13:00:00Z<![CDATA[PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference taking place virtually on Thursday, January 18, 2024, at 10:00 AM EST. Details are as follows:]]>https://www.globenewswire.com/news-release/2023/12/04/2790507/0/en/PDS-Biotechnology-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=53828PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)2023-12-04T21:50:00Z<![CDATA[PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced today that on December 4, 2023, PDS Biotech granted nonstatutory stock options to Lars Boesgaard, the Company’s new Chief Financial Officer, to purchase a total of 200,000 shares of the Company’s common stock as a material inducement to Mr. Boesgaard’s employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech’s 2019 Inducement Plan, as amended, which was adopted on June 17, 2019 and provides for the granting of equity awards to new employees of PDS Biotech.]]>https://www.globenewswire.com/news-release/2023/11/28/2786835/0/en/PDS-Biotech-Appoints-Lars-Boesgaard-as-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=53828PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer2023-11-28T12:30:00Z<![CDATA[PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced the appointment of Lars Boesgaard as Chief Financial Officer (CFO), effective as of December 4, 2023. Mr. Boesgaard succeeds Matthew Hill, who resigned as PDS Biotech’s CFO on November 21, 2023, effective December 1, 2023, to pursue other professional endeavors.]]>https://www.globenewswire.com/news-release/2023/11/14/2779977/0/en/PDS-Biotech-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=53828PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update2023-11-14T12:30:55Z<![CDATA[PRINCETON, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced its financial results for the quarter ended September 30, 2023. The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.]]>https://www.globenewswire.com/news-release/2023/11/09/2777276/0/en/PDS-Biotech-Announces-Updated-Survival-Data-from-NCI-Led-Phase-2-Clinical-Trial-of-PDS0101-Based-Triple-Combination-Therapy-in-Advanced-HPV16-Positive-Cancer-Patients-which-Show-75.html?f=22&fvtc=4&fvtv=53828PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months2023-11-09T13:00:00Z<![CDATA[PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced updated survival data from the Phase 2 clinical trial investigating the triple combination of PDS0101, PDS0301 (IL-12 antibody-drug conjugate) and an investigational immune checkpoint inhibitor (ICI) in two groups of advanced cancer patients with various types of human papillomavirus (HPV) 16-positive cancers. The ICI naïve group had not responded to standard-of-care treatments but had not yet been treated with an ICI. The ICI resistant group included patients who had not responded to multiple prior treatments, including ICI therapy. Investigators at the National Cancer Institute (NCI), part of the National Institutes of Health, have completed the primary endpoint analysis of the Phase 2 trial.]]>https://www.globenewswire.com/news-release/2023/11/07/2775014/0/en/PDS-Biotechnology-Announces-Conference-Call-and-Webcast-for-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=53828PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results2023-11-07T13:00:00Z<![CDATA[PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced that the Company will release financial results for the third quarter of 2023 on Tuesday, November 14, 2023, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.]]>